cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Acadia Pharmaceuticals Inc
25 own
40 watching
Current Price
$0
$0.32
(1.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,880.98M
52-Week High
52-Week High
26.04
52-Week Low
52-Week Low
12.24
Average Volume
Average Volume
0.35M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,880.98M
icon52-Week High26.04
icon52-Week Low12.24
iconAverage Volume0.35M
iconDividend Yield--
iconP/E Ratio--
What does the Acadia Pharmaceuticals Inc do?
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Read More
How much money does Acadia Pharmaceuticals Inc make?
News & Events about Acadia Pharmaceuticals Inc.
Business Wire
1month ago
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: BofA Securities 2023 Health Care Conference Fireside Chat: Wednesday, May 10, 2023 at 2:20 p.m. Eastern Time in Las Vegas, NV The JMP Securities Life Sciences...
Business Wire
1month ago
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Monday, May 8, 2023, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on May 8, 2023, at 4:30 p.m. Eastern Time to...
Business Wire
1month ago
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that four posters in Rett syndrome will be presented at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 27, 2023 in Boston, Mass. The poster presentations include a secondary analysis reporting on the...
Business Wire
1month ago
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that DAYBUE (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years of age and older in the United States. DAYBUE has demonstrated the potential to improve the signs and symptoms of Rett...
Business Wire
1month ago
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time. The conference will be held virtually. A live webcast of the presentation will be accessible on the companys...
Frequently Asked Questions
Frequently Asked Questions
What is Acadia Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Acadia Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Acadia Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Acadia Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Acadia Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Acadia Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Acadia Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Acadia Pharmaceuticals Inc?
plus_minus_icon
What percentage is Acadia Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Acadia Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.32
(1.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
LivaNova PLC
LivaNova PLC
$46.45
$0.85 (1.86 %)
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$41.71
$-1.23 (-2.88 %)
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
$38.83
$0.18 (0.45 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$48.84
$-0.72 (-1.45 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
LivaNova PLC
LivaNova PLC
$46.45
$0.85 (1.86 %)
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$41.71
$-1.23 (-2.88 %)
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
$38.83
$0.18 (0.45 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$48.84
$-0.72 (-1.45 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00